Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases

• Published in: Journal of oncology pharmacy practice Vol. 20; no. 2; pp. 120 - 129
• Main Authors: Eckmann, Karen, Michaud, Laura B, Rivera, Edgardo, Madden, Timothy L, Esparza-Guerra, Laura, Kawedia, Jitesh, Booser, Daniel J, Green, Marjorie C, Hortobagyi, Gabriel N, Valero, Vicente
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01-04-2014; Sage Publications Ltd
• Subjects: Adult; Aged; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Chemotherapy; Docetaxel; Female; Humans; Kinetics; Liver; Liver - drug effects; Liver - pathology; Liver Diseases - drug therapy; Liver Neoplasms - drug therapy; Liver Neoplasms - pathology; Liver Neoplasms - secondary; Male; Metastasis; Middle Aged; Pharmacology; Pilot Projects; Taxoids - adverse effects; Taxoids - pharmacokinetics; Toxicity; liver impairment; chemotherapy; Docetaxel; metastatic breast cancer; taxanes; hepatic dysfunction
• ISSN: 1078-1552; 1477-092X
• DOI: 10.1177/1078155213480536

Background:Limited clinical data are available regarding the safety of docetaxel in metastatic breast cancer patients with liver dysfunction.
Methods:Eligible patients had breast cancer with impaired liver function secondary to hepatic metastases and were candidates for docetaxel therapy. They were assigned to one of five groups on the basis of total bilirubin, alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase levels. All other causes of liver dysfunction were excluded, and bile duct obstruction was corrected, if possible, prior to study entry. Patients received docetaxel every three weeks. The chemotherapy dose was chosen on the basis of the patient’s level of hepatic dysfunction and escalated as tolerated. The primary outcome of this study was safety. The secondary outcomes were pharmacokinetic data and efficacy in terms of time to disease progression.
Results:Twenty-three patients were enrolled. No unexpected toxicities occurred. Grade 3/4 fatigue (65%), neutropenia (30%), myalgias (26%), neutropenic fever (26%), vomiting (9%), and rash (9%) were the most common serious adverse events. The median time to progression was three months (range 1–18 months). Pharmacokinetic results indicated that patients with more severe hepatic dysfunction may have been underdosed based on our conservative dosing strategy.
Conclusions:Docetaxel can be administered to patients with metastatic breast cancer and liver dysfunction after dose attenuation. However, because of a narrow therapeutic index in this clinical setting, therapy should be closely monitored with subsequent dose escalation when possible.